- Home
- INMB vs LTRN Comparison
INMB vs LTRN Comparison
Compare INMB & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- LTRN
- Stock Information
- Founded
- INMB 2015
- LTRN 2013
- Country
- INMB United States
- LTRN United States
- Employees
- INMB N/A
- LTRN N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- LTRN Health Care
- Exchange
- INMB Nasdaq
- LTRN Nasdaq
- Market Cap
- INMB 49.2M
- LTRN 49.9M
- IPO Year
- INMB 2019
- LTRN 2020
- Fundamental
- Price
- INMB $1.87
- LTRN $3.90
- Analyst Decision
- INMB Hold
- LTRN Strong Buy
- Analyst Count
- INMB 3
- LTRN 1
- Target Price
- INMB $4.30
- LTRN $25.00
- AVG Volume (30 Days)
- INMB 349.2K
- LTRN 164.4K
- Earning Date
- INMB 10-30-2025
- LTRN 11-14-2025
- Dividend Yield
- INMB N/A
- LTRN N/A
- EPS Growth
- INMB N/A
- LTRN N/A
- EPS
- INMB N/A
- LTRN N/A
- Revenue
- INMB $50,000.00
- LTRN N/A
- Revenue This Year
- INMB $264.29
- LTRN N/A
- Revenue Next Year
- INMB $9,819.61
- LTRN N/A
- P/E Ratio
- INMB N/A
- LTRN N/A
- Revenue Growth
- INMB N/A
- LTRN N/A
- 52 Week Low
- INMB $1.71
- LTRN $2.55
- 52 Week High
- INMB $11.64
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- INMB 45.15
- LTRN 42.88
- Support Level
- INMB $1.79
- LTRN $3.80
- Resistance Level
- INMB $1.95
- LTRN $4.28
- Average True Range (ATR)
- INMB 0.10
- LTRN 0.30
- MACD
- INMB 0.01
- LTRN -0.04
- Stochastic Oscillator
- INMB 46.00
- LTRN 14.29
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.